{
  "docId": "019de074-abc1-773c-9c2f-d49993e7b79a",
  "docSlug": "59a1ae16b5e60c748be3b046cd750424",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 20 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4138439,
  "pageNumber": 17,
  "pageCount": 20,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes specific study references and definitions for abbreviations like TGI and PDX.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-abc1-773c-9c2f-d49993e7b79a/17",
  "deckHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a",
  "deckJsonHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a.json",
  "deckAnchorHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "callout",
      "text": "Preclinical data for AZ-PRMT5i-1 showed robust pharmacodynamic and anti-tumour activity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e41a81d7-458a-4df0-a82d-e89612405dca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Efficacy in MTAP-null NSCLC PDX",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bd802bf-a297-47e4-90f7-6f0ce248055c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Efficacy in MTAP-null Gastric PDX",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "717fb23b-7cf9-4489-99ea-8a4ca2d0b9e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.35,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "AZ-PRMT5i-1 will continue to advance to Phase I.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51d10c38-35a3-4d02-96bd-bd282f48a75c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Epigenetic therapy is one of AstraZeneca’s six core scientific areas of focus. The modality is the latest addition to the Company’s diverse portfolio...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da482511-8cd5-45c5-ac26-9ae0579838b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "source-note",
      "text": "Smith JM et al. Identification of a novel series of MTAP-selective PRMT5 inhibitors...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b298e7d3-3930-4ded-8956-eb2ed736487e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "New at #AACR23: First disclosure and preclinical data for an epigenetics molecule targeting PRMT5",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19fe27cb-0ec0-4b98-8d60-86c680b2388b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.35,
        "y": 0.8
      },
      "kind": "title",
      "text": "What's next?",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c83ed2a7-31fa-4b68-b589-66aa8d5749bd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "56cdd0e4-2e0f-4301-9ad2-c8da972ed7de",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Details on novel treatments and pipeline advancements aim to satisfy the need with solutions.",
      "position": 3,
      "confidence": 0.7,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}